SciELO - Scientific Electronic Library Online

 
vol.27 número2Acute promyelocytic leukemia: characterization of chromosome abnormalities by classical cytogenetics and FISHImpact of deferral criteria on prevention of Creutzfeldt-Jakob disease and its variant among blood donors in São Paulo, Brazil índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Revista Brasileira de Hematologia e Hemoterapia

versión impresa ISSN 1516-8484

Resumen

LANDEIRO, Luciana et al. B-Cell depletion in the treatment of autoimmune cytopenias. Rev. Bras. Hematol. Hemoter. [online]. 2005, vol.27, n.2, pp. 102-105. ISSN 1516-8484.  http://dx.doi.org/10.1590/S1516-84842005000200009.

The morbidity associated with the treatment of autoimmune cytopenias has created a need for new approaches. Based on the fact that rituximab reacts specifically against the CD 20 antigen and induces B-cell depletion interfering with the production of auto-antibodies, five patients with autoimmune cytopenias were treated. All patients were previously refractory to conventional therapy and received 375 mg/m2 of rituximab infusion weekly, for four weeks. All patients improved either by increasing the number of cells or by being able to reach steroid suspension. No major reactions occurred during infusion, and no major infections occurred during the follow up. Rituximab appears to be active and safe for patients with autoimmune hemolytic anemia and thrombocytopenia, suggesting that this agent can play an important part in the therapeutic arsenal for autoimmune diseases.

Palabras llave : Autoimmune cytopenias; autoimmune thrombocytopenia; hemolytic anemia; rituximab.

        · resumen en Portugués     · texto en Portugués     · pdf en Portugués